HomeCompareARHCF vs EQR

ARHCF vs EQR: Dividend Comparison 2026

ARHCF yields 3.73% · EQR yields 4.73%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ARHCF wins by $69.5K in total portfolio value· pulled ahead in Year 2
10 years
ARHCF
ARHCF
● Live price
3.73%
Share price
$11.87
Annual div
$0.44
5Y div CAGR
38%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$110.0K
Annual income
$35,436.17
Full ARHCF calculator →
EQR
EQR
● Live price
4.73%
Share price
$58.58
Annual div
$2.77
5Y div CAGR
15.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$40.5K
Annual income
$3,819.61
Full EQR calculator →

Portfolio growth — ARHCF vs EQR

📍 ARHCF pulled ahead of the other in Year 2

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodARHCFEQR
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ARHCF + EQR cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ARHCF pays
EQR pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ARHCF
Annual income on $10K today (after 15% tax)
$317.42/yr
After 10yr DRIP, annual income (after tax)
$30,120.74/yr
EQR
Annual income on $10K today (after 15% tax)
$401.93/yr
After 10yr DRIP, annual income (after tax)
$3,246.67/yr
At 15% tax rate, ARHCF beats the other by $26,874.08/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ARHCF + EQR for your $10,000?

ARHCF: 50%EQR: 50%
100% EQR50/50100% ARHCF
Portfolio after 10yr
$75.2K
Annual income
$19,627.88/yr
Blended yield
26.10%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EQR right now

ARHCF
No analyst data
Altman Z
2.7
Piotroski
4/9
EQR
Analyst Ratings
16
Buy
28
Hold
2
Sell
Consensus: Hold
Price Target
$70.35
+20.1% upside vs current
Range: $63.00 — $78.50
Altman Z
1.8
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ARHCF buys
0
EQR buys
0
No recent congressional trades found for ARHCF or EQR in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricARHCFEQR
Forward yield3.73%4.73%
Annual dividend / share$0.44$2.77
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR38%15.8%
Portfolio after 10y$110.0K$40.5K
Annual income after 10y$35,436.17$3,819.61
Total dividends collected$81.4K$16.9K
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: ARHCF vs EQR ($10,000, DRIP)

YearARHCF PortfolioARHCF Income/yrEQR PortfolioEQR Income/yrGap
1$11,215$515.34$11,248$547.57$33.00EQR
2← crossover$12,746$745.43$12,701$666.53+$45.00ARHCF
3$14,731$1,092.59$14,405$814.59+$326.00ARHCF
4$17,390$1,628.56$16,413$999.84+$977.00ARHCF
5$21,087$2,479.63$18,795$1,232.92+$2.3KARHCF
6$26,441$3,877.88$21,639$1,527.95+$4.8KARHCF
7$34,563$6,271.21$25,057$1,903.80+$9.5KARHCF
8$47,555$10,572.56$29,197$2,385.87+$18.4KARHCF
9$69,645$18,761.12$34,250$3,008.70+$35.4KARHCF
10$109,957$35,436.17$40,467$3,819.61+$69.5KARHCF

ARHCF vs EQR: Complete Analysis 2026

ARHCFStock

Alfresa Holdings Corporation, through its subsidiaries, engages in the manufacture, wholesale, marketing, and import/export of pharmaceuticals, diagnostic reagents, and medical devices/equipment in Japan and internationally. It is involved in the ethical pharmaceuticals wholesaling business that offers diagnostic reagents and medical devices/equipment to hospitals, clinics, and dispensing pharmacies. The company also engages in self-medication products wholesaling business that offers over-the-counter drugs, including health foods, supplements, and other products to drug stores and pharmacies. In addition, it manufactures and markets active pharmaceutical ingredients, pharmaceuticals, diagnostic reagents, and medical devices, as well as undertakes contract manufacturing of pharmaceuticals. Further, the company's medical-related business includes its dispensing pharmacy and other medical-related activities. Alfresa Holdings Corporation was incorporated in 2003 and is based in Tokyo, Japan.

Full ARHCF Calculator →

EQRREIT

Equity Residential is committed to creating communities where people thrive. The Company, a member of the S&P 500, is focused on the acquisition, development and management of residential properties located in and around dynamic cities that attract high quality long-term renters. Equity Residential owns or has investments in 305 properties consisting of 78,568 apartment units, located in Boston, New York, Washington, D.C., Seattle, San Francisco, Southern California and Denver.

Full EQR Calculator →
📬

Get this ARHCF vs EQR comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ARHCF vs SCHDARHCF vs JEPIARHCF vs OARHCF vs KOARHCF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.